Organigram said it intends to acquire Sanity Group for up-front consideration of €113.4 million (about $133.6 million), a total that could double depending on financial performance.
“The proposed acquisition of Sanity Group marks a pivotal step in Organigram's global expansion strategy as a leader in the rapidly expanding cannabis industry,” said Organigram CEO James Yamanaka in a statement. “This transformational acquisition will bring together two market leaders, extend our commercial footprint into Europe, and strengthen our competitive edge in the world’s largest federally legal cannabis markets.”
Sanity Group’s primary operations are in Germany, a cannabis market that's growing thanks to increased adoption among physicians, broader patient access, and a favorable regulatory landscape following the 2024 cannabis law reform. The German medical cannabis market was valued at more than €2 billion (about $2.36 billion) in 2025, serving approximately 800,000 patients.
